If left undiagnosed and untreated for a prolonged period, fatty liver disease can progress to more serious conditions, such as cirrhosis and liver cancer.
All over the United States, countless research projects designed to improve outcomes have lost funding or been shut down. Even screening efforts targeting patients in impoverished communities have been impacted by these policies.
The first 250 patients has been enrolled in the CORCINCH-HF U.S. pivotal trial evaluating the AccuCinch Transcatheter Left Ventricular Restoration System in patients with HFrEF.
Even seeing a cardiologist once per year can help these patients elevate their long-term survival. Many stay home, however, missing out on potentially life-saving guidance and/or treatment.
Andreas Ruck, MD, discussed new registry data on Boston Scientific’s Acurate neo2 TAVR valve, comparing it to popular devices from Edwards Lifesciences and Medtronic.
Both operations can help obese patients lose weight, researchers noted, but gastric bypass surgery "may be associated with greater cardiovascular benefits."
